Scholar Rock’s Post

The #article published in J Chromatogr B Analyt Technol Biomed Life Sci: Due to the increasing evidence for therapeutic drug monitoring (TDM) of #kinase inhibitors, the need is growing for new assays to rapidly evaluate kinase inhibitor plasma concentrations. In this study, the author use the stable #isotope-labeled internal standards (SILIS), developed an LC-MS/MS assay for the rapid and simultaneous quantification of 21 #kinase inhibitors,this method can applicable for routine analyses in #clinical practice. 👉 For more detailed information: https://lnkd.in/gva6hMsv 👉 #MCE Related #Product Recommendation: Gefitinib-d8 https://lnkd.in/gt8-SMvs Dasatinib-d8 https://lnkd.in/gZ-b56qH Ceritinib-d7 https://lnkd.in/g_vyFc5x Osimertinib-13C,d3 https://lnkd.in/g8DSmmVs

Summary of Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials, including products from Avidity Biosciences, Dyne Therapeutics, Tallac Therapeutics, and Denali Therapeutics. https://lnkd.in/gMF8BRPp #AntibodyOligonucleotideConjugates #AOCs #AOC1001 #AOC1020 #DYNE101 #DYNE251 #TAC001 #DNL310

Looking to screen for #kinaseinhibitors or evaluate #receptortyrosinekinase (RTK) activity? Access the most comprehensive kinase product solutions covering an extensive portfolio of #cellularassays & #recombinantenzymes for #drugdiscovery screening & lead optimization. - Ideal for evaluating any kinase target-based signaling activity from >440 kinases (70% of human kinome) - Screen millions of wells to measure binding, Kd, & activity using the same enzymes used in KinaseProfiler™ - Evaluate kinase activation or pharmacological profiling using functional and cell-based assays Integrate Eurofins DiscoverX’s kinase solutions into your discovery & development pipelines to accelerate your therapeutic programs. https://lnkd.in/gVNQGg-8

The FDA has issued a final guidance on the clinical pharmacology aspects of antibody-drug conjugates (ADCs), a promising class of targeted cancer therapies that combine an antibody, a linker, and a cytotoxic drug. The guidance provides recommendations on the design and analysis of clinical studies to evaluate the pharmacokinetics, pharmacodynamics, drug interactions, and immunogenicity of ADCs. The guidance also addresses the challenges and opportunities of applying model-informed drug development approaches to ADCs. This guidance is expected to facilitate the development and approval of safe and effective ADCs for patients with cancer. FDA announces a final guidance on clinical pharmacology considerations and recommendations for antibody-drug conjugates development programs. #shenclinicalservices #fda #fdaregulations https://lnkd.in/d-asxqj2.

#ACROHighlights [Featured Product] 📣 Exciting news! Pfizer's Class 1 new drug, PF-06940434 injection, has been approved for clinical trials in China. This Integrin αv/β8 antagonist shows promising potential against tumors. By selectively binding and blocking the Integrin αv/β8 receptor, it prevents the activation of TGF-β1, enhancing anti-tumor immunity in the tumor microenvironment and promoting tumor cell death. Discover more about Integrin therapeutic drug development and explore our comprehensive range of high-quality Integrin recombinant proteins, covering all 24 subtypes! 🔬 💥Visit our official website: https://smpl.is/8ercr #Pfizer #clinicaltrial #IntegrinAntagonist #AntiTumorActivity #Immunotherapy #TumorMicroenvironment #ResearchandDevelopment #BioPharma #ACROBiosystems

https://lnkd.in/eexvtVRj MTTI reports on 225Ac-EBTATE at SNMMI Toronto MTTI will update findings on both 177Lu-EBTATE clinical and 225Ac-EBTATE preclinical work at SNMMI 2024 in Toronto (Booth#1819) Our  EvaThera drug platform exploits Evans blue albumin binding to extend in vivo circulatory half-life and tumor residence time, enabling effective use of significantly lower radiopharmaceutical activity and fewer dosing cycles vs. faster clearing PRRTs. 225Ac-EBTATE was effective against SCLC with 80% complete remissions and 100% survival. at 60% less administered radioactivity than 225Ac-DOTATATE and was well tolerated. Stop by and meet our team.

Bruton's tyrosine kinase (BTK) inhibitors have shown significant clinical efficacy, but an unmet clinical need remains due to acquired resistance. To address the problem of drug resistance, many strategies have been developed. Many companies are engaged in developing BTK PROTACs to overcome resistance issues associated with BTK inhibitors. BTK PROTACs promote the degradation of BTK protein, bypassing multiple resistance mechanisms and enhancing drug efficacy.  https://lnkd.in/gZgWTCPY #PROTAC #BTK #drugresistance

https://lnkd.in/eD7H9-Bx An absolutely fascinating publication from Biogen charting the discovery of their covalent BTK inhibitor BIIB129. Naturally the pervasive use of a "continuous-read kinetic enzyme assay to drive the medicinal chemistry effort" caught my eye 👀 For those interested in the kinetic themes around BTK inhibition explored in this excellent paper and a tried and tested approach to identifying novel covalent drugs, interpreting SAR and modulating the safety profile of irreversible drugs - start with this summary of BTK inhibitor inactivation kinetics 👇👇👇 https://lnkd.in/eBV4wfqs and then check out Enzymlogic for further kinetic case studies.

Immunoadoptive Cell Therapy (ImmunoACT) has received the marketing authorisation approval from the Central Drugs Standard Control Organization (CDSCO), of the first humanised CD19-targeted Chimeric Antigen Receptor T cell (CAR-T cell) therapy product for relapsed / refractory (r/r) B-cell lymphomas and leukemia in India. NexCAR19 (Actalycabtagene autoleucel) is an indigenously developed CD19 targeted CAR-T cell therapy. It is the first-of-its kind, a Made-in-India product and puts the nation firmly on the world map of advanced cell-and-gene therapies. #Nexcar19 #scienceandtechnology #pharmaceutical #technology #genetherapy #cartcelltherapy #biotechnology #ptbtians

Why this matters? Nurix Therapeutics has discovered a new type of mutation in a protein called BTK, which is involved in certain blood cancers. These mutations can make cancer cells resistant to current treatments. However, Nurix has developed a new drug, NX-2127, that can target and destroy these mutated proteins, offering a new way to treat patients who have developed resistance to existing therapies. NX-2127 has shown promising results in early clinical trials, effectively targeting the BTK protein in patients with chronic lymphocytic leukemia, a type of blood cancer. This suggests that the drug could be a valuable new option for treating various B-cell malignancies, which are cancers that affect a type of white blood cell. #biotech #innovation #bloodcancer